Abstract
MicroRNAs (miRNAs) are a new class of negative regulators that repress gene expression by pairing with their target messenger RNAs (mRNAs). There are hundreds of miRNAs coded in the human genome and thousands of target mRNAs participating in a wide variety of physiological processes such as development and cell identity. It is therefore not surprising that several recent reports involved deregulated miRNAs in the complex mechanism of human carcinogenesis, and proposed them as new key regulators to correct the unbalanced expression of oncogenes and tumour suppressor genes exhibited in cancer cells. This review summarises most of the recent patents related to the use of miRNA signatures in cancer diagnosis and prognosis, the detection and profiling of miRNAs from tumour samples and the identification of oncogenes and tumour suppressor genes targeted by miRNAs, as well as new cancer therapies based on miRNA modulators.
Keywords: RNA silencing, RNA interference, gene therapy, microRNA, miRNA, miRNA target, miRNA inhibitor, miRNA mimic, cancer, cancer therapy, cancer diagnosis, patent, Caenorhabditis elegans, Exportin-5, TRBP, RISC, cisplatin, doxorubicin, RISCs, PCR, real-time PCR, FRET, chronic lymphocytic leukaemia, mass spectrometry, ATRA, HSP90, human carcinogenesis
Recent Patents on Anti-Cancer Drug Discovery
Title: Silencing Human Cancer: Identification and Uses of MicroRNAs
Volume: 6 Issue: 1
Author(s): Francisco E. Nicolas, Sara Lopez-Gomollon, Alfonso F. Lopez-Martinez and Tamas Dalmay
Affiliation:
Keywords: RNA silencing, RNA interference, gene therapy, microRNA, miRNA, miRNA target, miRNA inhibitor, miRNA mimic, cancer, cancer therapy, cancer diagnosis, patent, Caenorhabditis elegans, Exportin-5, TRBP, RISC, cisplatin, doxorubicin, RISCs, PCR, real-time PCR, FRET, chronic lymphocytic leukaemia, mass spectrometry, ATRA, HSP90, human carcinogenesis
Abstract: MicroRNAs (miRNAs) are a new class of negative regulators that repress gene expression by pairing with their target messenger RNAs (mRNAs). There are hundreds of miRNAs coded in the human genome and thousands of target mRNAs participating in a wide variety of physiological processes such as development and cell identity. It is therefore not surprising that several recent reports involved deregulated miRNAs in the complex mechanism of human carcinogenesis, and proposed them as new key regulators to correct the unbalanced expression of oncogenes and tumour suppressor genes exhibited in cancer cells. This review summarises most of the recent patents related to the use of miRNA signatures in cancer diagnosis and prognosis, the detection and profiling of miRNAs from tumour samples and the identification of oncogenes and tumour suppressor genes targeted by miRNAs, as well as new cancer therapies based on miRNA modulators.
Export Options
About this article
Cite this article as:
E. Nicolas Francisco, Lopez-Gomollon Sara, F. Lopez-Martinez Alfonso and Dalmay Tamas, Silencing Human Cancer: Identification and Uses of MicroRNAs, Recent Patents on Anti-Cancer Drug Discovery 2011; 6 (1) . https://dx.doi.org/10.2174/157489211793980033
DOI https://dx.doi.org/10.2174/157489211793980033 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Activation of B Cells by a Dendritic Cell-Targeted Oral Vaccine
Current Pharmaceutical Biotechnology Nanoparticles for Gene Delivery: A Brief Patent Review
Recent Patents on Drug Delivery & Formulation A Review of Himalayan Medicinal Plants against Cancer
Current Traditional Medicine TRPV1 Function in Health and Disease
Current Pharmaceutical Biotechnology Modulation of Doxorubicin Mediated Growth Inhibition of Hepatocellular Carcinoma Cells by Platelet Lysates
Anti-Cancer Agents in Medicinal Chemistry Possible Consequences of Blocking Transient Receptor Potential Vanilloid 1
Current Pharmaceutical Biotechnology Can Medical Therapy Fix Sexual Dysfunction after Major Pelvic and Prostate Surgery and does it Work for Kidney Stones? Chemotherapy before Cystectomy, New Schemes for which Patients?
Current Drug Targets Transductional Targeting with Recombinant Adenovirus Vectors
Current Gene Therapy Application of NMR Metabolomics to Search for Human Disease Biomarkers
Combinatorial Chemistry & High Throughput Screening Interferon Therapy for Malignant Solid Tumors
Current Drug Therapy Preclinical and Clinical Studies on the Use of Platinum Complexes for Breast Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Curcumin and Liver Cancer: A Review
Current Pharmaceutical Biotechnology Bugs as Drugs: Understanding the Linkage between Gut Microbiota and Cancer Treatment
Current Drug Targets The Correlation between EGFR and Androgen Receptor Pathways: A Novel Potential Prognostic Marker in Gastric Cancer
Anti-Cancer Agents in Medicinal Chemistry Metal Complexes, their Cellular Targets and Potential for Cancer Therapy
Current Pharmaceutical Design Design and Characterization of Mucoadhesive Gelatin-Ethylcellulose Microparticles for the Delivery of Curcumin to the Bladder
Current Drug Delivery Synthesis and Applications of Hydrogels in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Fyn Kinase in Brain Diseases and Cancer: The Search for Inhibitors
Current Medicinal Chemistry Prodrugs in Genetic Chemoradiotherapy
Current Pharmaceutical Design Potential Molecular Targeted Therapeutics: Role of PI3-K/Akt/mTOR Inhibition in Cancer
Anti-Cancer Agents in Medicinal Chemistry